CX3CL1 and Miyoshi myopathy: Based on the International Staging System (ISS), we found that MM patients with ISS III had higher CX3CL1 BM levels as compared to those with ISS I and ISS II, as shown in Figure 1B (P = 0.0001 and P < 0.0001, Mann–Whitney test) (median range BM CX3CL1 level in ISS I = 0.770 (0.46–1.530) ng/ml; II = 0.71 (0.394–1.460) ng/ml; and III = 1.38 (0.53–2.23) ng/ml).